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The AKT–mTOR pathway harbors several known and putative oncogenes and tumor suppressors. In a
phenotypic screen for lymphomagenesis, we tested candidate genes acting upstream of and downstream from
mTOR in vivo. We find that Rheb, a proximal activator of mTORC1, can produce rapid development of
aggressive and drug-resistant lymphomas. Rheb causes mTORC1-dependent effects on apoptosis, senescence,
and treatment responses that resemble those of Akt. Moreover, Rheb activity toward mTORC1 requires
farnesylation and is readily blocked by a pharmacological inhibitor of farnesyltransferase (FTI). In
Pten-deficient tumor cells, inhibition of Rheb by FTI is responsible for the drug’s anti-tumor effects, such that
a farnesylation-independent mutant of Rheb renders these tumors resistant to FTI therapy. Notably, RHEB is
highly expressed in some human lymphomas, resulting in mTORC1 activation and increased sensitivity to
rapamycin and FTI. Downstream from mTOR, we examined translation initiation factors that have been
implicated in transformation in vitro. Of these, only eIF4E was able to enhance lymphomagenesis in vivo. In
summary, the Rheb GTPase is an oncogenic activity upstream of mTORC1 and eIF4E and a direct therapeutic
target of farnesyltransferase inhibitors in cancer.
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The PI3K/AKT pathway is a frequent target for mutational
activation in human cancer. Several genetic lesions up-
stream of mTOR have been identified that can activate the
AKT pathway, and these include mutations in PI3k, AKT/
PKB, or loss of the tumor suppressors PTEN, TSC1, or
TSC2 (for review, see Vivanco and Sawyers 2002). These
upstream lesions affect a variety of cellular processes in-
cluding protein translation via activation of mTOR. Simi-
larly, translation factors acting downstream from mTOR
are highly expressed in many cancers and sometimes
correlate with poor prognosis (Mamane et al. 2006).
Moreover, expression of individual translation factors
can transform rodent fibroblasts, and, in particular, the
eIF4E initiation factor can drive tumor formation in vivo
(Lazaris-Karatzas et al. 1990; Ruggero et al. 2004; Wendel
et al. 2004). Thus, genetic lesions acting both upstream
of and downstream from mTOR can promote tumorigen-
esis and are important in human cancer.
mTOR integrates protein translation with cellular nu-
trient status and growth signals. The mTOR kinase can
participate in two biochemically and functionally dis-
tinct complexes, mTORC1 and mTORC2. The mTORC1
complex is sensitive to inhibition with rapamycin and sig-
nals downstream to activate translation initiation. The
second complex, mTORC2, is resistant to rapamycin
and signals upstream to activate Akt via Ser 473 phos-
phorylation (for review, see Guertin and Sabatini 2007).
The GTPase Rheb (Ras homolog enriched in brain) is a
proximal activator of mTORC1 and translation initia-
tion. In addition, Rheb has the opposite effect on mTORC2
and produces inhibition of the upstream Akt pathway,
most likely this involves a feedback mechanism (Tee et al.
2002; Inoki et al. 2003).
The mTORC1 complex activates key components of
the translation initiation machinery. For example,
mTORC1 acts to liberate the eIF4E and eIF4A initiation
factors from their inhibitory binding proteins, thus al-
lowing them to enter the initiation complex (Hay and
Sonenberg 2004; Dorrello et al. 2006). While eIF4E is
considered the rate-limiting factor, efficient translation
requires that eIF4E act in concert with other factors.
These include the RNA helicase eIF4A and its activator
eIF4B, which act to unwind the 5 untranslated region
(UTR) of certain mRNAs. The eIF4G protein serves as a
scaffold for assembly of the initiation complex (for re-
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view, see Sonenberg and Hinnebusch 2007), and eIF2 is
a key negative regulator that can block translation in
response to phosphorylation by PKR (Protein kinase
RNA-activated) and other kinases (Clemens 2004). The
eIF4E translation factor can affect general translation,
but most importantly, eIF4E facilitates the translation of
subsets of mRNAs characterized by complex and struc-
tured 5UTRs, and these include transformation-relevant
genes and regulators of apoptosis like Bcl-xL, Mcl1 or Sur-
vivin (Polunovsky et al. 2000; Mamane et al. 2004, 2007;
Larsson et al. 2007; Silva and Wendel 2007).
The significance of genetic lesions acting upstream in
the Akt pathway in cancer is established (Vivanco and
Sawyers 2002). In contrast, the malignant potential of
direct activation of mTORC1 in the absence of addi-
tional Akt signals is controversial. For example, in-
creased expression or mutational activation of mTOR
has not been reported in cancer, and moreover, activa-
tion of mTORC1 can induce feedback mechanisms that
block pro-oncogenic signals emanating from Akt (Man-
ning et al. 2005).
Downstream from Rheb and mTORC1, the eIF4E trans-
lation factor can act as an oncogene in vitro and in vivo;
moreover, its expression has been associated with poor
prognosis in human cancer (Lazaris-Karatzas et al. 1990;
Ruggero et al. 2004; Wendel et al. 2004). A similar in
vitro transforming activity has been proposed for other
translation factors as well; however, clear in vivo evi-
dence of their oncogenic activity is lacking. Examples
include the eIF4G factor and also a mutant form of
eIF2/S51A, which eludes regulation by the PKR kinase.
Enforced expression of these proteins can cause malig-
nant transformation of rodent cells. Also, the RNA he-
licase eIF4A is controlled by the tumor suppressor gene
Pdcd4 (programmed cell death-4) and has been impli-
cated in cancer (Donze et al. 1995; Fukuchi-Shimogori et
al. 1997; Avdulov et al. 2004; Zakowicz et al. 2005; Hil-
liard et al. 2006).
We previously examined the oncogenic activities of
Akt and eIF4E using the Eµ-Myc mouse lymphoma
model and adoptive transfer of retrovirally modified he-
matopoietic progenitor cells (HPCs) (Wendel et al. 2004,
2007). We have now chosen a candidate screening ap-
proach to assess the in vivo oncogenic function of certain
factors acting either upstream of or downstream from
mTOR. Our results identify the tumor-promoting ability
of Rheb and direct mTORC1 activation and pinpoint the
initiation factor eIF4E as the key oncogenic activity
downstream from mTORC1. Moreover, Rheb activity
depends on farnesylation, and in some tumors, inhibi-
tion of Rheb mediates the anti-tumor effect of farnesyl-
transferase inhibitors (FTIs).
Results
We selected genes acting upstream of and downstream
from mTOR that have been implicated in transforma-
tion in vitro to assess their in vivo oncogenic potential.
For example, we tested direct mTORC1 activation by
different Rheb mutants and examined a series of trans-
lation factors. Specifically, we looked at myristoylated
Akt (Akt) (Wendel et al. 2004), wild-type Rheb, Rheb/
Q64L, a previously characterized mutant with twofold
increased activity toward mTORC1, and Rheb/5A, an
inactive Rheb mutant (Inoki et al. 2003). Downstream
from mTOR, we tested the translation initiation factors
eIF4E, eIF4GI, eIF4AI, eIF4B, and eIF2/S51A, a mutant
of eIF2 that disables the PKR phosphorylation site
(Donze et al. 1995). The cDNAs were cloned in an iden-
tical manner into the MSCV-IRES-GFP retroviral vector.
Efficient protein expression from the constructs was
confirmed in 3T3 fibroblasts (Supplemental Fig. 2A,B)
and the resulting tumors (Fig. 1D).
In order to test the ability of these candidate genes to
promote lymphomagenesis, we used adoptive transfer of
virally transduced Eµ-Myc transgenic HPCs into lethally
irradiated, wild-type, syngeneic animals, monitored the
animals by palpation and blood analysis, and tested aris-
ing tumors for expression of the GFP reporter (schematic
in Supplemental Fig. 1; Wendel et al. 2004).
As expected downstream from mTOR, eIF4E was able
to promote tumorigenesis in vivo (Fig. 1A; Wendel et
al. 2004). In contrast, the other translation factors—
Figure 1. In vivo candidate screen for lymphomagenesis iden-
tifies the tumorigenic activity of Rheb GTPase. (A,B) Kaplan-
Meier plots showing the latency to tumor development in mice
reconstituted with retrovirally transduced Eµ-Myc HPCs,
where day 0 is the day of HPC transplantation. A shows eIF4E
(red; n = 50), eIF4B (green; n = 11), eIF4AI (blue; n = 8), eIF2/
S51A (purple; n = 11), eIF4GI (orange; n = 12) and vector control
(black; n = 62); includes mice analyzed in parallel and historic
controls.B shows myrAkt (Akt; red; n = 24), Rheb (green; n = 9);
Rheb/Q64L (blue; n = 18), Rheb/5A (orange; n = 6), and vector
control (as in A). (C) Representative micrographs of the indi-
cated Eµ-Myc lymphomas (Control: V; Rheb/Q64L: Rheb; myrAkt:
Akt; eIF4E: 4E) stained with hematoxylin and eosin (H&E), anti-
bodies against phosphorylated Akt (Ser473) (P-Akt), phosphory-
lated ribosomal S6 protein (Ser240/244) (P-S6), or TUNEL and
Ki-67. (D) Immunoblot of lysates prepared from Eµ-Myc lym-
phomas (V) and Eµ-Myc lymphomas expressing Rheb/Q64L
(Rheb), myrAkt (Akt), and eIF4E (4E) probed with the indicated
antibodies.
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eIF4GI, eIF4AI, eIF4B, and eIF2/S51A—were unable to
produce an acceleration of tumor development compared
with vector controls (Vector vs. 4G, 4A, 4B, 2; P > 0.5)
(Fig. 1A). Nearly all tumors arising from eIF4E-trans-
duced HPCs expressed the GFP reporter, while the few
tumors that arose in the other animals were uniformly
GFP negative, indicating that they had arisen from non-
transduced Eµ-Myc HPCs (Supplemental Fig. 3). Appar-
ently, eIF4E is unique among the translation initiation
factors we analyzed in its ability to drive tumor devel-
opment in vivo.
The small GTPase Rheb was able to promote lym-
phomagenesis in vivo and clearly had oncogenic potential.
Mice receiving HPCs expressing wild-type Rheb or Rheb/
Q64L, an allele with increased activity toward mTORC1,
developed tumors with high penetrance and short la-
tency compared with vector controls or an inactive Rheb
mutant (Rheb/5A) (Fig. 1B) (P < 0.0001 for Rheb and
Rheb/Q64L vs. Vector or Rheb/5A). The tumorigenic po-
tency of Rheb was less than that of myristoylated Akt,
and Rheb/Q64L-induced tumors with a median latency
of 109.5 d compared with only 40 d for myristoylated
Akt (Rheb/Q64L vs. Akt, P < 0.001). Moreover, Rheb-
and Akt-expressing HPCs had a selective advantage and
were enriched during tumorigenesis. For example, with
only ∼25% of HPCs infected with the retroviral con-
structs coexpressing the GFP reporter (data not shown),
we observed that tumors arising from Akt-expressing
HPCs were almost invariably GFP-positive. Similarly,
Rheb and Rheb/Q64L expression resulted in 67% and
80% GFP-positive tumors compared with 0%–23% for
vector and other constructs (Supplemental Fig. 3). Thus,
Rheb can act as an oncogene and cooperate with c-Myc
in tumorigenesis in vivo.
Next we wanted to explore the mechanisms and con-
sequences of Rheb action in cancer. First, surface marker
expression revealed that Rheb-driven lymphoma had a
mature B-cell phenotype, marked by B220, CD19, and
IgM expression, which most closely resembled tumors
expressing eIF4E and was clearly distinct from Akt-driven
lymphoma (Supplemental Table 1). Consistent with
Rheb’s ability to activate mTORC1 and not mTORC2, the
Rheb-expressing tumors showed extensive phosphoryla-
tion of ribosomal S6 protein without detectable Ser 473
phosphorylation of Akt (Fig. 1C). All lymphomas were
highly proliferative and irrespective of genotype >80% of
viable lymphoma cells stained positive for Ki-67. More-
over, Rheb tumors resembled the tumors expressing Akt
or eIF4E in that they displayed a very low frequency of
apoptotic cells as determined by TUNEL assay (Fig. 1C).
Immunoblot analysis confirmed the signaling effects of
Rheb and Akt in vivo and showed high expression of the
anti-apoptotic Mcl1 protein, whose translation is con-
trolled in part by mTORC1 and eIF4E (Fig. 1D; Wendel et
al. 2007). Endogenous Rheb protein levels were some-
what heterogeneous across tumors and did not appear to
correlate with Akt pathway activating lesions in vivo or
expression of Akt in vitro (Supplemental Fig. 4A,B).
Thus, Rheb activates mTORC1 in vivo and can suppress
apoptosis in a manner comparable with Akt or eIF4E.
c-Myc initiated lymphomagenesis is largely limited by
apoptosis (Strasser et al. 1990; Schmitt et al. 2002). The
rapid onset of Rheb-expressing tumors, their low levels
of apoptosis, and high expression of the anti-apoptotic
Mcl1 protein suggest that Rheb may promote tumor for-
mation by opposing c-Myc-induced apoptosis. We
wanted to directly examine how Rheb affected apoptosis
in hematopoietic cells where apoptosis can be triggered
by cytokine withdrawal (Plas et al. 2001; Edinger and
Thompson 2004). Briefly, we introduced vectors coex-
pressing either Rheb, Akt, or Mcl1 along with a GFP
reporter into populations of FL5-12 cells such that the
transduced cells would compete with nontransduced
cells. Upon cytokine depletion, we observed massive
cell death and concomitant enrichment in the popula-
tions transduced with Rheb, Akt, or Mcl1 but not vector
controls (Fig. 2A). Next we tested if Rheb could oppose
apoptosis in c-Myc-expressing mouse embryo fibroblasts
(MEFs), where apoptosis is readily triggered by serum
withdrawal (Evan et al. 1992). Analysis of TUNEL (Fig.
2B) and propidium iodide uptake by flow cytometry
(Supplemental Fig. 5A,B) revealed that MEFs coinfected
with c-Myc and Rheb, Akt, or Mcl1 were relatively pro-
tected from apoptosis compared with vector controls.
Importantly, Rheb’s ability to block apoptosis required
activation of mTORC1 and treatment with 100 nM rapa-
mycin completely reversed the anti-apoptotic effects of
Rheb and Akt with little consequence in Mcl1-express-
ing cells (Fig. 2B; Supplemental Fig. 5A,B). Thus, in vitro,
Rheb can oppose apoptosis triggered by factor depletion
or c-Myc activation in an mTORC1-dependent and rapa-
mycin-sensitive manner.
The anti-apoptotic Bcl2 family protein, Mcl1, is con-
trolled through several mechanisms including transla-
tion. Accordingly, Mcl1 is up-regulated in cells express-
ing eIF4E and, moreover, Mcl1 can massively accelerate
lymhomagenesis in the Eµ-Myc lymphoma model (Wen-
del et al. 2007). Consistent with Rheb acting upstream of
mTORC1 and eIF4E, we observed similar increases in
Mcl1 protein expression in both Rheb- and eIF4E-ex-
pressing lymphomas (Fig. 1D). Acute expression of Rheb
in MEFs produced twofold increased Mcl1 protein levels
that were somewhat sensitive to rapamycin (Fig. 2C). As
expected, rapamycin treatment completely blocked
mTORC1 activation and phosphorylation of ribosomal S6
protein. Rapamycin treatment produced an increase in Akt
phosphorylation that is consistent with previously re-
ported feedback mechanisms and may involve S6 kinase
and Irs1 (Jaeschke et al. 2002; Sun et al. 2005). Increased
Akt activity can impede Mcl1 degradation and may explain
the partial effect of rapamycin treatment on Mcl1 protein
levels (Fig. 2C; Maurer et al. 2006). The ability of Rheb to
increase Mcl1 protein was partly due to translation, since
cells expressing Rheb contained on average 1.6-fold more
Mcl1 mRNA in the polysome fraction compared with con-
trols, and which remained unchanged in total mRNA (Fig.
2D). While small, this increase was consistent and re-
sembled in magnitude the effect of eIF4E expression on
Mcl1 translation (Wendel et al. 2007). Collectively, these
data indicate that increased production of Mcl1 may con-
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tribute to Rheb’s anti-apoptotic action in vitro and in tu-
mors.
To assess if Rheb could oppose c-Myc induced apopto-
sis in vivo, we tested whether Rheb could prevent p53
loss in lymphomas derived from p53+/− cells. Briefly, tu-
mors arising from Eµ-Myc/p53+/− HPCs invariably un-
dergo loss of heterozygosity (LOH) and inactivate the
remaining p53 allele. Expression of potent anti-apoptotic
activities, like Akt, Bcl-2, or eIF4E, obviates the need for
p53 loss, and tumors remain heterozygous (Schmitt et al.
2002; Wendel et al. 2004). Rheb expression in Eµ-Myc/
p53+/− HPCs produced tumors that retained the wild-
type p53 allele and, like eIF4E-expressing cells, did not
undergo LOH in the p53 locus (Fig. 2E). Thus, Rheb can
attenuate the apoptotic effects of c-Myc activation in
vivo in a manner comparable with Akt or eIF4E.
Cellular senescence is an important failsafe mecha-
nism against transformation and is directly induced by
certain oncogenes including Ras, Akt, and eIF4E (Ser-
rano et al. 1997; Ruggero et al. 2004; Chen et al. 2005).
We found Rheb can activate senescence in primary MEFs
just like Akt or Ras. Rheb expression causes morpho
logical changes (data not shown), induction of senescence-
associated -galactosidase (SA -Gal) (Fig. 3A), early
growth arrest (Vector vs. Rheb, P < 0.0001) (Fig. 3C), and
p16 protein induction (Fig. 3D). As expected, these effects
depended on p53 and did not occur in the context of
c-Myc expression (Fig. 3A,C; Ruggero et al. 2004). Nota-
bly, pharmacologic inhibition of mTORC1 with rapamy-
Figure 2. Rheb opposes apoptosis in an mTORC1-dependent
manner. (A) Flow cytometric analysis of mixed FL5-12 cell
populations partially transduced with vectors coexpressing GFP
(vector) and either myrAkt (Akt), Rheb/Q64L (Rheb), or Mcl1.
Indicated are the percentages of GFP expressing cells before
(+IL3) and after (−IL3) IL3-withdrawal. (B) TUNEL and DAPI
stains of primary MEFs transduced with c-Myc and either vec-
tor, Rheb/Q64L (Rheb), or Mcl1 24 h after apoptosis was trig-
gered by serum withdrawal in the presence or absence of 100
nM rapamycin; quantification of TUNEL positive cells is indi-
cated. (C) Immunoblot of lysates prepared from MEFs trans-
duced with empty vector or Rheb/Q64L (Rheb), either untreated
(U) or rapamycin-treated (RAP), and probed with antibodies
against phosphorylated Akt (Ser473), phosphorylated ribosomal
S6 (Ser240/244), Mcl1, or tubulin. Indicated is the relative quan-
tification of Mcl1 protein levels. (D) Quantitative real-time RT–
PCR of Mcl1 normalized to -actin from cDNA samples pre-
pared from MEFs transduced with vector or Rheb/Q64L (Rheb).
Shown is a “relative quantification” whereby the Mcl1 expres-
sion in triplicates of the total and polysome samples from vector
transduced cells is set to 1 and compared with the total and
polysome fraction from cells expressing Rheb/Q64L. (E) Allele-
specific PCR to detect the wild-type p53 (WT) and mutant (M)
allele in tumors derived from Eµ-Myc/p53+/− HSCs transduced
with vector (V), Rheb/Q64L (Rheb) or eIF4E (4E).
Figure 3. Rheb induces cellular senescence in a p53, mTORC1-
dependent, and c-Myc-sensitive manner. (A) Representative mi-
crographs of wild-type (WT), p53−/−, and c-Myc-expressing MEFs
transduced with vector, Ras/V12 (Ras), Rheb/Q64L (Rheb), or
myrAkt (Akt) and stained for senescence-associated -galacto-
sidase (SA -Gal) activity. The mean and standard deviation of
the percentages of SA- Gal-positive cells are indicated; no
number indicates mean <1%. (B) Wild-type MEFs (WT) trans-
duced with the same expression constructs and treated with 100
nM rapamycin. Mean and standard deviation (n = 3) of SA -
Gal-positive cells for untreated and rapamycin-treated wild-
type MEFs is indicated. (C) Growth curves of wild-type, p53−/−-,
and c-Myc-expressing MEFs expressing vector (black line),
Rheb/Q64L (Rheb; blue line), Ras/V12 (Ras; red line), or myrAkt
(Akt; green line). (D) Immunoblot of lysates prepared from wild-
type MEFs transduced with the indicated alleles and either left
untreated (−) or treated with 100 nM rapamycin (+) and probed
for the indicated proteins.
Rheb oncogenicity
GENES & DEVELOPMENT 2181
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
cin could prevent many phenotypic changes associated
with senescence induced by Akt and Rheb and had a
partial effect on Ras-induced senescence (Fig. 3B,D).
Thus, Rheb can block c-Myc-induced apoptosis, and con-
versely, c-Myc may interfere with senescence activation
by Rheb—likely, these interactions underlie the ob-
served oncogenic cooperation of c-Myc and Rheb.
Mutational activation of the AKT pathway can have
profound effects on treatment responses in cancer
(Dilling et al. 1994; Wendel et al. 2004). To examine how
Rheb would affect the long-term effects of therapy in
vivo, we transplanted tumors expressing Akt, Rheb, or
chemo-sensitive controls (Eµ-Myc/Arf−/−) into recipient
animals. Upon tumor formation, we initiated treatment
with doxorubicin, a chemotherapeutic topoisomerase-2
poison and principle agent in lymphoma therapy, the
mTORC1 inhibitor rapamycin, and a combination of
both drugs (Wendel et al. 2004). We monitored mice for
complete remissions, defined as the absence of detect-
able disease by palpation and blood smear, and deter-
mined the time to relapse (Supplemental Fig. 6) and sur-
vival to preterminal condition (Fig. 4). As expected, Akt
reduced the effectiveness of treatment with doxorubicin,
which induced complete remissions and prolonged sur-
vival in animals harboring control lymphoma (Fig. 4A).
Rheb expression had similar effects on tumor-free sur-
vival as Akt (Control vs. Akt or Rheb, P = 0.007) (Supple-
mental Fig. 6A) and resulted in a significant survival dif-
ference compared with controls (Control vs. Akt, P = 0.02;
Control vs. Rheb, P = 0.004) (Fig. 4A). Consistent with pre-
vious observations in Akt-expressing tumors (Wendel et al.
2004), single agent treatment with rapamycin was un-
able to produce significant effects in Rheb or Akt tumors
and did not improve survival (Control vs. Akt or Rheb,
P > 0.1 for tumor-free and overall survival) (Fig. 4B;
Supplemental Fig. 6B). In contrast, combination treat-
ment more than doubled the mean survival times in Akt
(47 d) and Rheb (44 d) tumor-bearing mice compared
with chemo-sensitive controls (21 d) (Control vs. Akt or
Rheb, P < 0.0001) (Fig. 4C) and induced correspondingly
longer remissions (Supplemental Fig. 6C). Thus, Rheb
can reduce the effectiveness of chemotherapy, and this
consequence of increased Rheb expression is readily re-
versed by inhibition of mTORC1.
Rheb is a homolog of Ras and requires post-transla-
tional prenylation for proper localization and activity
(Castro et al. 2003; Buerger et al. 2006). However, unlike
Ras, Rheb is not a substrate for geranylgeranyltransfer-
ases and can only undergo farnesylation (Gau et al. 2005).
We speculated that this specific requirement for farne-
sylation should allow therapeutic inhibition of Rheb
with FTIs. To assess if FTI could block mTORC1 acti-
vation by Rheb, we transduced lymphoma cells with an
activated allele (Rheb/Q64L) and a mutant that does not
require farnesylation and instead undergoes geranylger-
anylation (Rheb/Q64L/M184L; referred to throughout
the figures as Rheb/M184L) (Gau et al. 2005). FTI (FTI-
277 at 20 µM) was able to block mTORC1 activation by
Rheb/Q64L as indicated by decreased phosphorylation of
ribosomal S6 protein in lymphoma cells (Fig. 5A). In con-
trast, mTORC1 activation by the geranylgeranylated
mutant (Rheb/Q64L/M184L) was insensitive to FTI (Fig.
5A). The effect of FTI on Rheb signaling was independent
of genotype and occurred equally in Arf−/− lymphocytes,
that do not activate the Akt pathway, and also in Pten-
deficient cells (Eµ-Myc/Pten+/−), which engage the Akt
pathway (Supplemental Fig. 7). Similarly, FTI-277 treat-
ment was able to induce cell death in both the chemo-
sensitive EµMyc/Arf−/− and the relatively chemo-resis-
tant Eµ-Myc/Pten+/− cells (Fig. 5B; Wendel et al. 2006).
Thus, FTI treatment can block Rheb activity and induce
anti-tumor effects in lymphoma cells.
A variety of proteins undergo farnesylation, and it has
been unclear which of these is the relevant target of FTI
therapy. We wondered if Rheb inhibition might be re-
sponsible for the anti-tumor effects of farnesyltransfer-
ase inhibition. Using retroviral vectors that coexpress
the GFP reporter, we transduced subpopulations of lym-
phoma cells with the active and FTI-sensitive Rheb mu-
tant (Rheb/Q64L) and the farnesylation-independent
Rheb allele (Rheb/Q64L/M184L), along with empty vec-
tor and Mcl1, and monitored the percentage of cells ex-
pressing the GFP reporter before and after FTI treatment.
In this “competition assay,” an increase in GFP indicates
that cells expressing a certain allele have a selective ad-
vantage compared with the uninfected population.
Figure 4. Rapamycin reverses Rheb-mediated resistance to
chemotherapy. Kaplan-Meier analyses of survival to pretermi-
nal condition in mice that were injected with control (Eµ-Myc/
Arf−/−; black lines), Rheb/Q64L (Rheb; green lines), and myrAkt
lymphoma cells (Akt; red lines). Treatment was initiated upon
detection of well-palpable tumors on day 0. (A) Doxorubicin
treatment (10 mg/kg) on day 1 of mice bearing control (n = 19),
Akt (n = 16), and Rheb (n = 8) lymphoma. (B) Rapamycin treat-
ment (4 mg/kg) on days 1, 3, and 5 of control (n = 11), Akt
(n = 14), and Rheb lymphoma (n = 8). (C) Combination therapy
with doxorubicin (10 mg/kg on day 1) and rapamycin (4 mg/kg
on days 1, 3, and 5) of mice harboring control (n = 22), Akt
(n = 15), and Rheb (n = 10) tumors. Treatment with rapamycin
and doxorubicin significantly prolonged survival in mice bear-
ing Akt- and Rheb-expressing tumors.
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Briefly, in Eµ-Myc/Pten+/− tumor cells, the geranylgeran-
ylated Rheb/Q64L/M184L allele was able to bypass the
anti-proliferative effect of the FTI, such that cells ex-
pressing this allele were massively enriched under FTI
treatment (Fig. 5C). A similar resistance to FTI was seen
with the anti-apoptotic Mcl1, while enforced expression
of the FTI-sensitive Rheb/Q64L allele was unable to pro-
tect against FTI and behaved like the empty vector (Fig.
5C). The ability of Rheb/Q64L/M184L to confer FTI re-
sistance was genotype-dependent, and we did not ob-
serve a similar enrichment of Rheb/Q64L/M184L-express-
ing cells in the Eµ-Myc/Arf−/− background (Fig. 5C). This
likely indicates that different mechanisms contribute to
FTI drug action in genetically distinct tumors. In sum-
mary, Rheb inhibition by FTIs is responsible for their
activity against tumors harboring activating lesions in
the Akt pathway.
Our results establish that Rheb can have profound ef-
fects in a murine model of lymphoma. To understand its
relevance to human lymphoma, we examined the ex-
pression of RHEB across a panel of Burkitts’ and diffuse
large B-cell lymphoma (DLBCL). We found a substantial
heterogeneity and a third, 8 of 24 cases, showed modest
(between threefold and 10-fold) increases in RHEB ex-
pression compared with reactive tonsils, and individual
cases had 20-fold and even 43-fold elevation of RHEB
mRNA levels (Fig. 6A). As seen in the analysis of murine
lymphoma (Fig. 1C,D), high RHEB expression in human
tumors produced activation of mTORC1 and phosphor-
ylation of the ribosomal S6 and inhibitory eIF4E-binding
proteins (4E-BP1) (Fig. 6B). The reason for overexpression
in these tumors is not clear. We observed only a twofold
increase in gene copy number in the highest RHEB-ex-
Figure 5. Rheb inhibition by FTIs is responsible for FTI’s anti-
tumor effect in Pten-deficient lymphoma. (A) Immunoblot of
lysates prepared from Arf−/− lymphocytes expressing Rheb/Q64L
or Rheb/Q64L/M184L (Rheb/M184L) and either untreated (U) or
treated with 100nM rapamycin (R) for 6 h, or 20 µM FTI-277 for 24
h (F) and probed with antibodies against phosphorylated (Ser240/
244) and total ribosomal S6 and tubulin. (B) Flow cytometric
analysis of Eµ-Myc/Pten+/− and Eµ-Myc/Arf−/− tumor cells at
different times after treatment with FTI-277 (20 µM). Indicated
is the fraction of viable cells of all nucleated cells. (C) Flow
cytometric analysis of mixed PTEN+/− or Arf−/− lymphoma cell
populations partially transduced with vectors coexpressing GFP
and either Rheb/Q64L, the farnesylation-independent mutant
Rheb/Q64L/M184L (Rheb/M184L) or Mcl1. Indicated are the
percentages of GFP-expressing cells before and after treatment
with FTI-277 (30 µM/48 h).
Figure 6. RHEB expression and drug sensitivity in human lym-
phoma. (A) Quantitative real-time RT–PCR analysis of RHEB
expression from cDNAs prepared from reactive tonsils (tonsil),
a collection of DLBCL, and some cases of Burkitt’s (Burkitt)
lymphoma. (B) Representative micrographs of lymphomas #5,
#23, and #24 representing low and high RHEB mRNA-express-
ing lymphoma in A. Samples are stained with hematoxylin and
eosin (H&E), and antibodies against the indicated antigens. (C)
Quantitative real-time RT–PCR analysis of RHEB expression in
human lymphoma cells lines representing DLBCL and Burkitt’s
lymphoma compared with reactive tonsils. (D) Immunoblot of
lysates prepared from low (LY8) and high (LY18) RHEB-express-
ing DLBCL lines probed with the indicated antibodies. (E) Mean
and standard deviation of viability of LY8 and LY18 human
lymphoma lines treated with FTI-277 at the indicated concen-
trations for 48 h.
Rheb oncogenicity
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pressing tumors (Supplemental Fig. 8). The RHEB pro-
moter region and first exon do not contain significant
CpG islands (data not shown). And while the promoter
contains potential c-Myc-binding sites (Li et al. 2003), we
saw no correlation between c-MYC and RHEB expres-
sion levels in our lymphoma samples (Supplemental Fig.
9A,B). The expression of a second RHEB gene (RHEB L1)
showed little variation between normal and tumor
samples (Supplemental Fig. 10). And while a recent large-
scale effort has identified tumor-associated mutations in
RHEB (Wood et al. 2007), we did not detect mutations in
the RHEB coding sequence (data not shown). Taken to-
gether, RHEB is highly expressed in some human lym-
phomas, and while the mechanism is not clear, RHEB
expression corresponds to increased mTORC1 activation
in these cases.
To assess if this heterogeneous RHEB expression could
also impact drug action in human lymphoma, we ana-
lyzed RHEB expression in several well-characterized hu-
man cell lines derived from Burkitts’ and DLBCL lym-
phoma (Mehra et al. 2002). As in the primary tumors, we
observed significant heterogeneity and overall higher
RHEB expression levels (Fig. 6C). For example, the LY18
line showed >100-fold increase in RHEB mRNA com-
pared with the LY8 line. Similar to the murine lym-
phoma, these changes were accompanied by increased
expression of the RHEB and MCL1 proteins and phos-
phorylation of ribosomal S6 (Fig. 6D). The LY8 and LY18
cell lines are not syngeneic, both have inactivating mu-
tations in the p53 tumor suppressor, and while both
carry translocations affecting the c-MYC locus, they dif-
fer in c-MYC expression (Supplemental Fig. 9A; Mehra et
al. 2002). Upon in vitro treatment of LY8 and LY18 with
doxorubicin or rapamycin alone, we observed no signif-
icant differences (LY8 vs. LY18, P > 0.5) (Supplemental
Fig. 11A,B). In contrast, the high RHEB-expressing LY18
line and the low RHEB LY8 cell lines significantly dif-
fered in their susceptibility to the chemo-sensitizing ef-
fect of rapamycin (P < 0.01) (Supplemental Fig. 11C).
Similarly, the high Rheb-expressing LY18 cells were some-
what more sensitive to FTI-277 compared with the LY8
cell line (P = 0.002 by students t-test) (Fig. 6E; Supplemen-
tal Fig. 12). These results indicate that heterogeneous
RHEB expression in human lymphoma may pinpoint tu-
mors with an increased sensitivity to pharmacologic inhi-
bition of RHEB farnesylation and mTORC1 activity.
Discussion
Our study illustrates the potential of genetically versa-
tile mouse models and adoptive transfer strategies to
functionally evaluate candidate oncogenes and explore
rational therapeutic strategies in vivo. For example, we
surveyed the in vivo oncogenic potential of genes acting
upstream of and downstream from mTOR and in trans-
lation initiation. We identify Rheb, a proximal activator
of mTORC1, as a novel oncogenic activity capable of
enhancing lymphomagenesis in vivo. Notably, it has
been controversial if mTORC1 activation can affect can-
cer phenotypes in the absence of additional Akt signals.
For example, neither activating mutations nor increased
expression of mTOR have been reported in cancer, and
the functional consequence of a recently reported, tu-
mor-associated RHEB mutation is unclear (Wood et al.
2007). Similarly, genetic inactivation of TSC1 and TSC2,
which act upstream of RHEB and mTORC1, but also
affect mTORC2, is associated only with benign tumor
syndromes (Manning et al. 2005; Huang et al. 2008).
However, other findings suggest the potential impor-
tance of mTORC1 in cancer. For example, inhibition of
mTORC1 with rapamycin can produce anti-tumor ef-
fects in some tumors (Dilling et al. 1994; Wendel et al.
2006), and conversely, mTORC1 activation can blunt
the anti-proliferative effects of genetic Akt inactivation
in vitro (Skeen et al. 2006). We find that mTORC1 acti-
vation by Rheb is able to drive tumorigenesis and affect
apoptosis, cellular senescence, and treatment responses.
Moreover, RHEB is highly expressed in some human
lymphoma and possibly other cancers (Lassman et al.
2005). Our findings indicate that Rheb contributes to the
malignant phenotype and may affect clinical behavior
and treatment responses.
Downstream from mTOR we looked at certain com-
ponents of the translation initiation complex that have
been implicated previously in cellular transformation in
vitro. Specifically, we examined the initiation factors
eIF4AI, eIF4B, and eIF4GI, which act in concert with the
oncogenic eIF4E factor and also a mutant form of eIF2
(eIF2/S51A) that is resistant to PKR-mediated transla-
tion inhibition. At least in the Eµ-Myc context, we find
that only eIF4E is able to promote tumor development in
vivo. While it remains possible that the other translation
factors can contribute to cancer in other settings, our
results underscore the unique role of eIF4E as a transla-
tion factor capable of driving tumor development in vivo
and are consistent with a rate-limiting role of eIF4E in
the translation of transformation-relevant proteins
(Polunovsky et al. 2000; Hay and Sonenberg 2004; Wen-
del et al. 2004; Mamane et al. 2007).
Oncogenesis driven by c-Myc is largely opposed by ap-
optosis (Strasser et al. 1990; Schmitt et al. 2002; Wendel
et al. 2004), and we find that Rheb, like eIF4E and Akt, is
able to counter the pro-apoptotic activity of c-Myc. Con-
versely, c-Myc can interfere with the induction of cellu-
lar senescence by Rheb and Akt as well as eIF4E (Rug-
gero et al. 2004). These interactions likely explain the
oncogenic cooperation between c-Myc and distinct acti-
vating lesions in Akt-mTOR signaling and translation
initiation. Besides these broad similarities, there are no-
table differences between oncogenic factors acting at dif-
ferent points in the Akt pathway. For example, myris-
toylated Akt has a relatively stronger oncogenic effect
compared with Rheb and produces tumors that express a
distinct pattern of surface markers possibly indicating
a different cellular origin. Likely this reflects additional
tumor-promoting activities and evasion of negative feed-
back controls by this constitutively active form of Akt.
For example, mTORC1 activation has been shown to
produce feedback inhibition of Akt, which can limit the
transforming potential of TSC1/2 inactivation (Ma et al.
Mavrakis et al.
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2005; Manning et al. 2005). We can speculate that simi-
larly, disruption of feedback controls as seen upon loss of
Pten may further potentiate Rheb’s oncogenicity.
Acting downstream from mTORC1, eIF4E produces
tumors that are phenotypically very similar to Rheb-
driven tumors. However, eIF4E tumors are insensitive to
rapamycin. Moreover, eIF4E expression is sufficient to
bypass the anti-tumor effects of rapamycin, indicating
that eIF4E is a critical downstream mediator of
mTORC1 activity (Wendel et al. 2004). And while Rheb
certainly has additional targets (Clark et al. 1997; Im et
al. 2002), we find that Rheb’s transformation-relevant
effects on apoptosis, cellular senescence, and also che-
motherapy responses are strictly dependent on mTORC1
activation and are sensitive to rapamycin. Together,
these genetic findings suggest an epistatic relation be-
tween the pro-oncogenic activities of Rheb, mTORC1,
and eIF4E.
Activation of Rheb and mTORC1 or increased abun-
dance of the initiation factor eIF4E can affect the trans-
lation of a wide range of proteins; however, there are also
specific effects on the translation of proteins involved in
cellular transformation and apoptosis (Sonenberg and
Hinnebusch 2007). For example, the anti-apoptotic Mcl1
protein is a transformation-relevant protein whose trans-
lation is increased upon expression of eIF4E or Rheb. In
addition, Mcl1 is highly expressed in murine and human
lymphomas driven by Rheb or eIF4E and is itself capable
of enhancing c-Myc-induced lymphomagenesis (Wendel
et al. 2007). Clearly, Mcl1 is regulated through nontrans-
lational mechanisms as well (Le Gouill et al. 2004), and
in addition to Mcl1, other regulators of apoptosis includ-
ing Bcl-xL or Survivin can be affected by changes in
translational regulation (Polunovsky et al. 2000; Raja-
sekhar et al. 2003; Larsson et al. 2007; Mamane et al.
2007). We can conclude that Mcl1 may exemplify how
changes in translational efficiencies of specific proteins
can contribute to the anti-apoptotic and tumor-promot-
ing effects of eIF4E or Rheb.
Our findings on oncogenic activities upstream of and
downstream from mTOR have implications for cancer
therapy. For example, the unique oncogenic potency of
the eIF4E translation factor provides a further rationale
for targeting eIF4E in cancer therapy. In particular,
eIF4E’s dual regulation by the Akt and Mapk pathways
may be amenable to targeted inhibitors of these signaling
pathways (Silva and Wendel 2007; Wendel et al. 2007).
Rheb’s transformation-relevant activities depend on
mTORC1 activation. Accordingly, mTORC1 inhibition
by rapamycin may present a rational therapeutic strategy
in Rheb-expressing cancers. Supporting this conclusion,
we observe that rapamycin improves treatment responses
in Rheb-driven tumors in vivo and also sensitizes human
lymphoma cells that express high levels of RHEB to DNA-
damaging agents in vitro. However, targeted inhibition of
signaling pathways can have broad effects on cellular and
organismal physiology, and some effects may counter
their therapeutic purpose. For example, rapamycin may
enhance upstream oncogenic signals through feedback
mechanisms (Sun et al. 2005), and, at least in cells that
have not disabled this failsafe mechanism, rapamycin
can affect aspects of the senescence phenotype and po-
tentially enhance proliferation of cells. In addition, rapa-
mycin is a potent immunosuppressive. Thus, markers
are needed to identify patients for whom the anti-tumor
effects outweigh unwanted treatment consequences.
RHEB expression in tumors may be a predictor of sensi-
tivity to rapamycin or direct Rheb inhibition.
FTI can directly block Rheb activity and induce cyto-
toxic effects in human and murine lymphoma cells. No-
tably, FTIs were first devised to inhibit Ras; however,
alternative prenylation of K- and N-Ras hinders these
drugs’ ability to affect Ras oncogenes (for review, see
Braun and Fenaux 2008). Nonetheless, FTIs are less toxic
than chemotherapy and have notable activity in acute
leukemias, where they produce responses in up to 30%
and complete remissions in some 10%–15% of patients.
These clinical effects do not appear to be linked to Ras
mutations or inhibition of Ras effectors (Kurzrock et al.
2004; Burnett and Kell 2007; Lancet et al. 2007). It is
therefore likely that other substrates of farnesyltransfer-
ase contribute to the anti-cancer effects of FTI therapy,
and several farnesylated proteins have been implicated
including Rheb, H-Ras, Lamin A, Lamin B, RhoB, and
the centromere proteins CENP-E and CENP-F (Du and
Prendergast 1999; Castro et al. 2003; Basso et al. 2005;
Gau et al. 2005; Karbowniczek et al. 2008). We find that
FTIs can inhibit Rheb in lymphoma cells, and that inhi-
bition of Rheb is responsible for the anti-tumor effect of
FTIs in Pten-deficient tumor cells. Accordingly, a farne-
sylation-independent mutant of Rheb can confer resis-
tance to FTI in tumors that activate Akt signaling. In
contrast, in tumor cells that do not engage the Akt path-
way, the constitutive Rheb allele is unable to bypass the
cytotoxic effect of the inhibitor. It is well established
that FTIs can affect the activity of several signaling mol-
ecules (Braun and Fenaux 2008), and that the relative
importance of these pathways differs between geneti-
cally distinct tumors (Wendel et al. 2004). In this way,
the genetic context can determine FTI activity, and also
which mechanism is responsible for FTI anti-tumor ac-
tion.
Together, our study defines Rheb as an oncogenic
activity that is amenable to rational therapeutic strate-
gies using rapamycin or direct inactivation with inhibi-
tors of farnesyltransferase. RHEB is highly expressed in
some human cancers, including lymphoma, and may




Lymphomas were generated and analyzed as described (Schmitt
et al. 2002). The retroviruses used to produce tumors and used
in cell assays were based on MSCV-IRES-GFP and expressed
cDNAs encoding eIF4E, eIF4B, eIF4AI, eIF2/S51A, eIF4GI, and
myristoylated Akt (Wendel et al. 2004), and Rheb, Rheb/Q64L,
and Rheb/5A (Inoki et al. 2003). Mice were monitored by blood
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count and palpation, and lymphomas were harvested and either
fixed for histological evaluation, rendered single cell suspen-
sions and frozen in 10% DMSO, or transplanted directly into
normal mice for treatment studies.
Treatment studies
Treatment studies were performed as described previously
(Wendel et al. 2004). Briefly, 1 × 106 DMSO frozen or primary
lymphoma cells were injected into the tail vein of 6- to 8-wk-old
female C57BL/6 mice. Upon the formation of well-palpable
tumors, the animals were treated with rapamycin (LC Labs;
4 mg/kg, i.p.), doxorubicin (Sigma; 10 mg/kg, i.p.), or a combi-
nation of both. In treatment studies, control lymphomas were
Eµ-Myc/Arf−/− tumors, which are homogeneous with respect to
p53 status. Following treatment, the mice were monitored by
twice weekly palpation and blood smears stained with Giemsa
(Fisher Diagnostics). Tumor-free and overall survival data were
analyzed in the Kaplan-Meier format using the log-rank (Man-
tel-Cox) test for statistical significance.
Histopathology
Preparation of samples, H&E stain, and detection of antibody
stains were as described previously (Wendel et al. 2004). Anti-
bodies were against phosphorylated ribosomal S6 protein
(Ser240/244; Cell Signaling, #2215 and #4857), phosphorylated
Akt (Ser473; Cell Signaling, #9271), phosphorylated 4E-BP1
(Cell Signaling, #2855), and Ki67 (NovoCastra, NCL-Ki67-P).
TUNEL was performed using a published protocol (McCurrach
and Lowe 2001).
Immunophenotyping
Tumor cell suspensions of representative tumors of each genotype
were stained as described (Wendel et al. 2004). The antibodies
were B220/CD45R (PharMingen, #553089), CD19 (PharMingen,
catalog no. 557399), IgM/IgK (PharMingen, #555584), Thy1/CD90
(Cedarlane, #CL8610PE), CD4 (PharMingen, #557308), CD8
(PharMingen, #553032), Sca-1 (PharMingen, #553108), or c-kit
(PharMingen, #553869) conjugated with phycoerythrin and ana-
lyzed with a Guava EasyCyte Plus system.
Cell culture and viability
Primary MEFs were cultured as described (McCurrach and Lowe
2001). FL5-12 cells were maintained in RPMI-1640 medium
supplemented with 10% FBS, 10% WEHI-3B conditioned me-
dium, and interleukin-3 (400 pM) (Plas et al. 2001). For apoptosis
assays, MEFs were transduced with pBabe-Myc, selected with
puromycin (2.5 µg/mL), and subjected to serum withdrawal for
12–24 h in the presence or absence of rapamycin during the
same period. For cytokine depletion, FL5-12 cells were washed
four times in PBS and resuspended in growth media without
interleukin-3 or WEHI-3B conditioned media (Plas et al. 2001).
FTI-277 (Calbiochem) was dissolved in DMSO and used at no
more than 0.1% of final volume; for immunoblots, cells were
treated for 24 h and 48 h in viability and competition experi-
ments. Viability was determined by trypan blue stain and
TUNEL assay as described (McCurrach and Lowe 2001). Flow
cytometric analysis of cell death was by Viacount, which con-
tains a cell-permeable dye (LDS-751) and the non-membrane-
permeable propidium iodide (Guava #4500-0160).
Cell senescence assay
Early passage MEFs were infected and selected for growth curves;
cells were plated at 104 cells, and cell numbers were determined at
various time points. Cells were untreated or treated twice with
rapamycin 100 nM and collected 7 d post-selection for immuno-
blotting and senescence-associated -galactosidase (SA -Gal) as
described (Serrano et al. 1997).
Western blot analysis
Immunoblots were performed as described (Wendel et al. 2004)
using antibodies against Rheb (1:1000; Cell Signaling, #4935),
total and phosphorylated (Ser473) Akt (1:1000; Cell Signaling,
#9272, #9271), total and phosphorylated (Ser240/244) ribosomal
S6 (1:1000; Cell Signaling, #2317, #2215), p16 (1:1000; Santa
Cruz Biotechnologies, M-156), p53 (1:500; Novocastra, NCL-
p53-505), p21 (1:1000; Santa Cruz Biotechnologies, c-19), mouse
Mcl1 (1:1000; Abcam, ab32087-100), human MCL1 (1:1000;
Santa Cruz Biotechnologies, S-19), Tubulin (1:5000; Sigma, B-5-
1-2), Actin (1:5000; Sigma, AC-15), and anti-HA (1:5000; Roche,
#12013819).
Polysome fractionation
As described in detail in Xi et al. (2004), cells were treated with
cycloheximide before harvesting and lysing. The nuclei were
pelleted, and the ribosomal components were separated from
the soluble fraction by ultracentrifugation. RNA was isolated
using Trizol (Invitrogen), and cDNA synthesis was performed
using the SuperScriptIII kit (Invitrogen). RT–PCR primers were
Mcl1F, AGCCTGACTTCCCAGCTCAC; Mcl1R, GCACTCA
GACCACATGCTTC; ActinF, AAGCTAACCGGGAGAAGA
TG; and ActinR, GTAGTCAGTGAGGTCGCGAC.
Expression and gene copy number analyses
Total RNA was extracted using Allprep DNA/RNA/Protein kit
(Promega, #80004). cDNA synthesis was by SuperScript III Re-
verse Transcriptase (Invitrogen, #18080-400), and PCR was per-
formed in triplicate using the DNA Engine 7900HT FAST Real
time PCR system (Applied Biosystems) and TaqMan Universal
PCR Master Mix (Roche, 4304437). The human RHEB (assay ID:
Hs00950803_m1), MYC (assay ID: Hs00153408_m1), GUSB
(#4333767T), and PGK1 (#4333765T) primers were from Taq-
Man Gene Expressions Assays. Target gene expression was
quantified by normalizing against endogenous controls GUSB or
PGK using the  Ct method. The gene copy number of RHEB
was determined by quantitative PCR using RHEB forward/re-
verse primers (Forward, 5-CTGAGGCCGCCAAG-3; reverse,
5-CTCCAAACTTCGCAGGCC-3) and a TaqMan dual-labeled
MGB probe corresponding to intronic sequence AAGTCCCGG
AAGATCGCGATCCTG. The relative quantification of RHEB
was referenced to RNase P and compared with male genomic
DNA.
Sequence analysis
RHEB cDNA was amplified from DLBCL first strand synthe-
sized cDNA by using the following RHEB forward/reverse prim-
ers: Forward, 5-CAGGAGCCACCGCCGCCGCGGTT-3; Re-
verse, 5-GAATATATTCCCAGTGTCCTCAGGC-3). For the
sequencing reaction, the following nested primers were used:
Forward, 5-TGTGGTTGGGCCGGGGCTGAGGAGGC-3; Re-
verse, 5-TCAGGCTTTGCAGCAGAATCA-3. Analysis was per-
formed on an ABI 3730 Capillary Sequencer.
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